EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A Post–NGP Mitsuokella jalaludinii as a Therapeutic Candidate for Gout

Mohammed Solayman Hossain iD, Sukyung Kim, Md Tareque Aziz, Izaz Ahmed, Md Sarower Hossen Shuvo iD, Hyewon Yang iD, Yunjeong Jang, Minseo Kim, Seohyeon Jang, Yusol Kim, Soeun Oh, Yunseo Nam iD und 2 weitere

MicrobiologyOpen · 2026

DOI: 10.1002/mbo3.70410 ↗

Kurz gefasst

Fachartikel in der Zeitschrift MicrobiologyOpen, 2026. Verfasst von Mohammed Solayman Hossain und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology and Immunology, School of Medicine, Soonchunhyang University, Cheonan, Chungnam, Republic of Korea. Hauptthemen laut MEDLINE: Gout, Probiotics. Die Arbeit nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea (NRF), Establishment of Innovative Infrastructure for Manufacturing process for Next-Generation Microbiome Drugs, Ministry of Employment and Labor's K-Digital Training Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Gout is a common inflammatory disease closely associated with hyperuricemia, and its global prevalence is increasing, highlighting the need for safer and more effective therapeutic strategies. Recently, microbiome‐based therapeutics have emerged as promising alternatives, and the development of functionally validated NGP and their advanced forms, post–NGP strains, is gaining increasing attention. In this study, microbiome‐derived bacterial strains were screened based on their in vitro uric acid (UA)‐reducing capacity and hypoxanthine utilization. Among the tested strains, Mitsuokella jalaludinii exhibited the most pronounced uric acid reduction and growth enhancement in response to purine substrates compared to conventional lactic acid bacteria. This strain reduced uric acid levels by approximately 30% after 48 h ( p < 0.001) and showed significantly increased growth in purine‐enriched minimal medium ( p < 0.01). WGS further confirmed its strain‐level novelty, leading to its designation as PMC73, and revealed the presence of genetic features associated with purine metabolism and UA regulation. In a MSU‐induced RAW 264.7 macrophage model, PMC73 significantly reduced UA levels ( p < 0.001) and modulated immune responses by increasing anti‐inflammatory cytokines while decreasing pro‐inflammatory cytokines. These effects were associated with suppression of the NLRP3–caspase‐1, along with downregulation of URAT1 and XOD, indicating coordinated regulation of uric acid production, reabsorption, and inflammatory pathways. Based on safety evaluation, including d ‐lactate production, cytotoxicity assays and oral toxicity assessment in a mouse model, demonstrated that PMC73 exhibited no pathogenic or toxic properties. Therefore, PMC73 represents a promising microbiome‐based candidate with relevance to gout‐associated hyperuricemia, warranting further in vivo and clinical investigations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GoutProbioticsAnimalsMiceUric AcidPurinesRAW 264.7 CellsHyperuricemiaHypoxanthineMacrophagesCytokinesHumans

Stichwörter der Autor:innen

M. jalaludinii PMC73goutgut microbiomehyperuricemianext‐generation probiotics (NGP)post–NGP

Substanzen

Uric AcidPurinesHypoxanthineCytokines

Autor:innen und Institutionen

  • Department of Microbiology and Immunology, School of Medicine, Soonchunhyang University, Cheonan, Chungnam, Republic of Korea.
  • K-Microbiome Institute, Asan, Chungnam, Republic of Korea.
  • Next-Generation Microbiome Training Center, Soonchunhyang University, Asan, Chungnam, Republic of Korea.

ORCID-Profile: Mohammed Solayman Hossain, Md Sarower Hossen Shuvo, Hyewon Yang, Yunseo Nam, Ho-Yeon Song

Förderung

  • National Research Foundation of Korea (NRF)
  • Establishment of Innovative Infrastructure for Manufacturing process for Next-Generation Microbiome Drugs
  • Ministry of Employment and Labor's K-Digital Training Project
  • Soonchunhyang University Research Fund

Zitieren

APA

Hossain, M. S., Kim, S., Aziz, M. T., Ahmed, I., Shuvo, M. S. H., Yang, H., Jang, Y., Kim, M., Jang, S., Kim, Y., Oh, S., Nam, Y., Seo, H., & Song, H. Y. (2026). A Post–NGP Mitsuokella jalaludinii as a Therapeutic Candidate for Gout. MicrobiologyOpen. https://doi.org/10.1002/mbo3.70410

Vancouver

Hossain MS, Kim S, Aziz MT, Ahmed I, Shuvo MSH, Yang H, et al. A Post–NGP Mitsuokella jalaludinii as a Therapeutic Candidate for Gout. MicrobiologyOpen. 2026. doi:10.1002/mbo3.70410

BibTeX
@article{Hossain2026,
  author = {Hossain, Mohammed Solayman and Kim, Sukyung and Aziz, Md Tareque and Ahmed, Izaz and Shuvo, Md Sarower Hossen and Yang, Hyewon and Jang, Yunjeong and Kim, Minseo and Jang, Seohyeon and Kim, Yusol and Oh, Soeun and Nam, Yunseo and Seo, Hoonhee and Song, Ho-Yeon},
  title = {A Post–NGP Mitsuokella jalaludinii as a Therapeutic Candidate for Gout},
  journal = {MicrobiologyOpen},
  year = {2026},
  doi = {10.1002/mbo3.70410}
}
Kostenlos starten →